EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modulation of Plasmatic Matrix Metalloprotease 9: A Promising New Tool for Understanding the Variable Clinical Responses of Patients with Cystic Fibrosis to Cystic Fibrosis Transmembrane Conductance Regulator Modulators

Michela Capraro, Marco Pedrazzi iD, Roberta De Tullio iD, Marcello Manfredi iD, Federico Cresta iD, Carlo Castellani iD, Monica Averna iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241713384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Michela Capraro und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine (DIMES), University of Genova, 16126 Genova, Italy. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Cystic Fibrosis Research Foundation, University of Genova, Ph.D. School of the Department of Experimental Medicine (University of Genova).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The most recent modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta®), has been shown to improve clinical outcomes in most patients with cystic fibrosis (PwCF). Unfortunately, the clinical benefits are sometimes variable; thus, improving our knowledge of the possible causes of this variability can help reduce it.

Methods

Circulating mononuclear cells (CMCs) and plasma were collected from 16 PwCF (including those on Trikafta® therapy) and 4 non-CF subjects. Cystic fibrosis transmembrane conductance regulator (CFTR) activity and matrix metalloprotease 9 (MMP9) expression were monitored before and after therapy, together with some clinical parameters. The relationship between MMP9 expression and the modulation of the extracellular-regulated 1/2 (ERK1/2) and nuclear factor-kB (NF-kB) pathways was also analyzed.

Results

MMP9, markedly expressed in the CMCs and plasma of all the patients included in the study, was downregulated in the clinically responsive PwCF. In the non-responder, the MMP9 levels remained high. The modulation of MMP9 following treatment with Trikafta® may be controlled by the NF-kB pathway.

Conclusions

These data strongly suggest that MMP9 downregulation is a potential biomarker of therapy efficacy and that it could be useful in understanding the molecular events underlying the variable clinical responses of patients to Trikafta®. This knowledge could be helpful for future studies of personalized medicine and thereby ensure improvements in individual responses to therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorMatrix Metalloproteinase 9Arachnoid CystsNF-kappa BHumansHearing Loss, SensorineuralAgenesis of Corpus Callosum

Stichwörter der Autor:innen

ERK1/2NF-kBTrikafta®biomarkercirculating mononuclear cells (CMCs)cystic fibrosispersonalized medicine

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorMatrix Metalloproteinase 9NF-kappa B

Autor:innen und Institutionen

  • Department of Experimental Medicine (DIMES), University of Genova, 16126 Genova, Italy.
  • Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy.
  • Cystic Fibrosis Center Genova, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.

ORCID-Profile: Marco Pedrazzi, Roberta De Tullio, Marcello Manfredi, Federico Cresta, Carlo Castellani, Monica Averna

Förderung

  • Italian Cystic Fibrosis Research Foundation
  • University of Genova
  • Ph.D. School of the Department of Experimental Medicine (University of Genova)

Zitieren

APA

Capraro, M., Pedrazzi, M., De Tullio, R., Manfredi, M., Cresta, F., Castellani, C., & Averna, M. (2023). Modulation of Plasmatic Matrix Metalloprotease 9: A Promising New Tool for Understanding the Variable Clinical Responses of Patients with Cystic Fibrosis to Cystic Fibrosis Transmembrane Conductance Regulator Modulators. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241713384

Vancouver

Capraro M, Pedrazzi M, De Tullio R, Manfredi M, Cresta F, Castellani C, et al. Modulation of Plasmatic Matrix Metalloprotease 9: A Promising New Tool for Understanding the Variable Clinical Responses of Patients with Cystic Fibrosis to Cystic Fibrosis Transmembrane Conductance Regulator Modulators. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241713384

BibTeX
@article{Capraro2023,
  author = {Capraro, Michela and Pedrazzi, Marco and De Tullio, Roberta and Manfredi, Marcello and Cresta, Federico and Castellani, Carlo and Averna, Monica},
  title = {Modulation of Plasmatic Matrix Metalloprotease 9: A Promising New Tool for Understanding the Variable Clinical Responses of Patients with Cystic Fibrosis to Cystic Fibrosis Transmembrane Conductance Regulator Modulators},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241713384}
}
Kostenlos starten →